Harvard Bioscience, Inc. Receives NSF Grant For New High Throughput Toxicity Screening Assays
HOLLISTON, Mass., May 24 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it and the University of Wisconsin, Madison, had received a grant from the National Science Foundation to expand development of its novel MitoScan®96 toxicity screening assays, which offer rapid, convenient alternatives to cellular assays.
The grant is a two year, SBIR/STTR Phase II type in the amount of $492,000. The grant will be used by Harvard Bioscience to develop dedicated instruments that will accommodate both cuvette and 96-well microplate-based formats.
The MitoScan®96 assays have been established to have a very high correlation with whole organism and cell based assays. MitoScan®96 requires no advance cell preparation. MitoScan®96 eliminates cell isolations and cell culture. Because there are no cells to be cultured, the various associated tasks such as washing, extraction, filtration and centrifugation are eliminated. A 96 well micro plate can be processed and results analyzed in less than 30 minutes whereas cell based assays require days.
Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, and Germany with sales facilities in France and Canada.
Statements in this release that relate to expectations and objectives of management for future operations of Harvard Bioscience, Inc., or that otherwise relate to future performance, are forward looking statements. Actual results may differ from those projected as a result of product demand, pricing, market acceptance, economic conditions, intellectual property issues, competitive products, risks in product and technology development, and other risks identified in our Securities and Exchange Commission fillings.
Press releases and our product catalog can be found on our web site, http://www.harvardbioscience.com.
SOURCE Harvard Bioscience, Inc.
CONTACT: Jim Warren, CFO, jwarren@harvardbioscience.com, or David Green, President, dgreen@harvardbioscience.com, or Chane Graziano, CEO, cgraziano@harvardbioscience.com, all of Harvard Bioscience
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.